Compare MPLX LP (MPLX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Novartis AG — how do they compare? MPLX LP trades at $57.42 (market cap $58.11B), while Novartis AG trades at $142.86 (market cap $268.57B). The key difference: Novartis AG is far larger — about 4.6× MPLX LP's market cap, and MPLX LP pays the higher dividend (7.51%). Which is the better fit depends on your goals.
| MPLX | NVS | |
|---|---|---|
Market Cap | $58.11B | $268.57B |
Volume | 687,483 | 1,532,573 |
Sector | Energy | Health |
52-Week High | $60.51 | $168.62 |
52-Week Low | $47.80 | $121.80 |
Enterprise Value | $83.22B | $309.89B |
Dividend Yield | 7.51% | 3.31% |
Typical Hold Time | — | 82 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $57.05, down 1.25% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations in Q1 and Q2 2026. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and a resilient midstream business model that limits commodity price exposure.
The outlook is cautiously optimistic given MPLX's fee-based revenue structure and 67.86% buy rating from analysts. Key risks include energy market volatility and potential diesel export restrictions, but the company's distribution coverage ratio of 1.3x supports dividend sustainability. Upside potential exists if Q3 earnings meet or exceed the $1.15 EPS estimate due November 3, 2026.
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
